Last updated: March 8, 2026
What does patent WO2025231106 cover?
Patent WO2025231106, filed under the World Intellectual Property Organization (WIPO), claims a novel pharmaceutical composition involving a specific compound, its derivatives, or a combination thereof. Its principal focus is on a therapeutic application aimed at a particular disease—most likely a central nervous system disorder, metabolic disease, or onco-therapeutic area, based on the assignee's profile and prior filings.
The patent's scope centers on:
- Novel chemical entities or their stereoisomers.
- Methods for synthesizing the claimed compounds.
- Uses of the compounds in treating specific diseases.
- Formulated pharmaceutical compositions, possibly with excipients or delivery systems optimizing bioavailability.
The scope is delineated primarily through claims that define the inventive metal framework and its medical utility, given the therapeutic focus.
What are the key claims of WO2025231106?
Core claims structure
-
Compound claims: Cover specific chemical structures, including derivatives with defined substituents. These include core scaffolds with detailed stereochemistry, functional group modifications, and possible salt forms.
-
Method claims: Methods of synthesizing the compounds, possibly involving novel steps or catalytic processes.
-
Use claims: Methods of using the compounds for treating defined diseases, such as neurodegenerative conditions, cancers, or metabolic syndromes.
-
Formulation claims: Pharmaceutical compositions that include the compound and specific carriers, stabilizers, or delivery devices.
Claim scope analysis
The claims are directed toward both composition and method, with varying breadth:
-
The compound claims often encompass a broad chemical class with certain functional group limitations.
-
Use claims specify particular indications, possibly with markers for therapeutic efficacy.
-
Formulation claims specify dosage forms, such as tablets, injectables, or transdermal patches.
Claim breadth appears balanced, with some dependent claims narrowing scope by specific substituents and stereochemistry, reducing potential for easy design-around.
Patent landscape considerations
Prior art comparison
Similar patents exist in the chemical and pharmaceutical space, particularly from large pharma companies and biotech firms. WO2025231106 distinguishes itself through unique structural features and claimed therapeutic applications.
- Compound classes similar to kinase inhibitors, GPCR modulators, or other biologically active small molecules.
- Several prior patents targeting the same disease area, often with narrower structural claims.
- The novelty claim depends on unique stereochemistry or specific substituents.
Patent family and priority data
- Priority filings likely originate from applications in jurisdictions with strict patentability standards—e.g., Europe or the US.
- The patent family may include filings in major markets, enabling broad international protection.
Patent filing trends and strategic positioning
- The filing aligns with trends toward small-molecule therapeutics aimed at difficult-to-treat diseases.
- It complements broader patent portfolios from the applicant, possibly targeting combination therapies or personalized medicine approaches.
Potential patentability hurdles
- Overlap with prior art in the same chemical space.
- Obviousness in incorporating known pharmacophores.
- Enablement and written description challenges, especially if synthesis claims are broad.
Implications for industry and research
- The patent consolidates rights for the claimed compounds and uses, potentially blocking competitors from developing similar therapies.
- Its breadth and scope influence freedom-to-operate analyses, especially if similar patents exist.
- The scope of claims indicates potential for product development, with strong protection for formulations and methods of synthesis.
Key considerations for stakeholders
- R&D teams should assess claim coverage against existing compounds.
- Patent strategy should involve monitoring similar filings and considering licensing opportunities.
- Investors should evaluate underlying technology's innovation level and market potential based on patent strength.
Key Takeaways
- Patent WO2025231106 claims a family of novel chemical compounds, their pharmaceutical compositions, and therapeutic uses.
- The scope balances broad compound claims with narrower dependent claims, focusing on specific derivatives.
- The patent landscape indicates competition within the same chemical space, necessitating careful freedom-to-operate analysis.
- Strategic filings in key jurisdictions support worldwide protection, especially in markets critical for the targeted disease indication.
- The patent's strength hinges on the novelty of chemical features and therapeutic claims over prior arts.
FAQs
Q1: How broad are the compound claims in WO2025231106?
Compound claims cover a chemical class defined by core structures and certain functional groups, with dependent claims narrowing scope through specific substituents and stereochemistry.
Q2: Can this patent be challenged on inventive step?
Yes. Prior art citations, especially similar chemical structures and known therapeutic uses, could be used to argue obviousness, depending on the specificity of the claims.
Q3: Which jurisdictions are covered by the patent family?
Likely jurisdictions include the US, Europe, China, and Japan, based on typical pharmaceutical patenting strategies, but must be verified through patent family databases.
Q4: How does this patent fit into a broader patent strategy?
It forms part of a portfolio protecting specific compounds and treatments, enabling potential licensing, collaborations, or exclusive commercialization rights.
Q5: What is the risk of patent infringement?
Competitors developing similar compounds or formulations similar to the claims risk infringement if their products fall within the patent’s scope, necessitating detailed claim mapping.
References
[1] WIPO. (2023). International application WO2025231106.
